< Return to Virtual Testing Guide

Blood Specimen Collection

Download DLO's Blood Specimen Collection Chart

For additional supply or collection device information, please contact DLO's Customer Services at (800) 891-2917, option 2.

< Return to Virtual Testing Guide

Ammonia

Test Code: 5509

Alternative Name(s): Not applicable

Methodology: Enzymatic

< Return to Virtual Testing Guide

Alcohol, Ethyl (B)

Test Code: 443

Includes: Alcohol, Ethyl

Methodology: Alcohol dehydrogenase

Alternative Name(s): Alcohol, Ethyl

< Return to Virtual Testing Guide

Cardio IQ® Omega-3 and -6 Fatty Acids

Test Code: 91734

Methodology: Chromatography/Mass Spectrometry
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano, CA. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Includes: Omega-3 (EPA+DHA) Index, Omega-6/Omega-3 Ratio, EPA/Arachidonic Acid Ratio, Arachidonic Acid, EPA, DHA

< Return to Virtual Testing Guide

Cortisol, A.M.

Test Code: 4212

Methodology: Immunoassay (IA)

Clinical Significance: Cortisol is increased in Cushing's Disease and decreased in Addison's Disease (adrenal insufficiency).

Alternative Name(s): N/A

< Return to Virtual Testing Guide

Cystic Fibrosis Screen

Test Code: 10458

Alternative Name(s): CF Mutation Screen,Cystic Fibrosis Mutation Screen,CFTR Screen,CF Carrier Screen,CF Screen,Cystic Fibrosis Carrier Screen

Methodology: Multiplex Polymerase Chain Reaction • Massively Parallel Sequencing

Clinical Significance: General screen for carrier status and assessment of CF risk. This test will identify approximately 90% of Cystic Fibrosis (CF) mutations in the Caucasian population, and 97% in the Ashkenazi Jewish population.

< Return to Virtual Testing Guide

ANA Screen, IFA, with Reflex Titer/Pattern

Test Code: 8268

Methodology: Immunofluorescent Assay (IFA)

Clinical Significance: Antinuclear antibodies are associated with rheumatic diseases including Systemic Lupus Erythematous (SLE), mixed connective tissue disease, Sjogren's syndrome, scleroderma, polymyositis, CREST syndrome, and neurologic SLE.

Includes: The ANA Screen, IFA, with Reflex Titer/Pattern

If ANA Screen, IFA is positive, then ANA Titer and Pattern will be performed at an additional charge (CPT code(s): 86039).

< Return to Virtual Testing Guide

Complement Components C3 & C4

Test Code: 5704

Includes: Complement Component C3C; Complement Component C4C

Methodology: Immunoturbidimetric

Clinical Significance: Decreased concentrations of both C3 and C4 suggest activation of the classical pathway, whereas decreased concentration of just C3 suggests activation of the alternative pathway. Both complement factors may be used to monitor activity of patients with systemic lupus erythematosus (SLE) and immune complex-induced vasculitis.

< Return to Virtual Testing Guide

CMV, DNA, QN, PCR, Plasma ***Transplant Patients ONLY***

Test Code: 59720

Methodology: Real-time PCR

Clinical Significance: CMV is an important pathogen in the transplant setting causing pneumonitis, colitis, hepatitis, CNS disease, neutropenia, and disseminated disease. Prior to the availability of rapid and sensitive DNA PCR, CMV was a leading cause of morbidity and mortality in the transplant population. Quantitative CMV DNA PCR can be used for early detection of CMV reactivation, primary infections, and monitoring response to treatment.

Pages